Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

PubWeight™: 0.89‹?›

🔗 View Article (PMID 25307130)

Published in Ophthalmology on October 11, 2014

Authors

Michael M Altaweel1, Ebenezer Daniel2, Daniel F Martin3, Robert A Mittra4, Juan E Grunwald2, Michael M Lai5, Alexander Melamud5, Lawrence S Morse6, Jiayan Huang2, Frederick L Ferris7, Stuart L Fine8, Maureen G Maguire2, Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group

Author Affiliations

1: Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin. Electronic address: mmaltaweel@wisc.edu.
2: Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
3: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
4: VitreoRetinal Surgery, Edina, Minnesota.
5: Retina Group of Washington, Chevy Chase, Maryland.
6: Department of Ophthalmology, University of California-Davis Medical Center, Sacramento, California.
7: Epidemiology and Clinical Research, National Eye Institute, Bethesda, Maryland.
8: Department of Ophthalmology, University of Colorado-Denver, Aurora, Colorado.

Associated clinical trials:

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial | NCT00593450

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration | NCT03699618

Articles cited by this

Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63

Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84

Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42

Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 12.01

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol (1999) 9.80

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29

Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina (1996) 2.27

Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology (2004) 2.19

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2012) 2.19

Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol (1990) 1.83

Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol (1982) 1.74

Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.73

Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement. Arch Ophthalmol (2001) 1.73

Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70

Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina (2007) 1.68

Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina (2010) 1.54

Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol (1991) 1.52

Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica (1999) 1.46

Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. Ophthalmology (2011) 1.33

Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina (2010) 1.32

Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2000) 1.28

Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina (2007) 1.23

Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging (2010) 1.12

Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. Clin Ophthalmol (2010) 1.11

Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization. Ophthalmology (2013) 1.06

Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy. Am J Ophthalmol (2013) 1.05

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol (2007) 1.05

Retinal pigment epithelium tears following ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol (2006) 1.02

Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage. Invest Ophthalmol Vis Sci (2008) 1.00

Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol (2011) 0.99

Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol (2011) 0.96

Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy. Am J Ophthalmol (2009) 0.92

Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy. Retina (2013) 0.89

Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration. Retina (2014) 0.89

Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage. Acta Ophthalmol (2011) 0.84

Surgical treatment of age-related macular degeneration. Semin Ophthalmol (2011) 0.82

Anti-VEGF response in macular hemorrhage and incidence of retinal pigment epithelial tears. Can J Ophthalmol (2013) 0.78

Evolving strategies in the management of submacular hemorrhage associated with choroidal neovascularization in the anti-vascular endothelial growth factor era. Retina (2011) 0.77

Articles by these authors

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 3.85

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 1.45

Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol (2014) 1.20

Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.07

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 1.04

Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. JAMA Ophthalmol (2016) 0.96

Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.94

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.88

Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology (2014) 0.87

Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2015) 0.86

Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2015) 0.85

Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 0.84

Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 0.83

Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology (2015) 0.82

Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology (2015) 0.82

The Practice Impact of Electronic Health Record System Implementation Within a Large Multispecialty Ophthalmic Practice. JAMA Ophthalmol (2015) 0.82

VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. Ophthalmology (2015) 0.79

Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.78

Endothelial PAS domain-containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the comparison of AMD treatments trials (CATT). Ophthalmology (2014) 0.78

Timely implementation of a retinopathy of prematurity telemedicine system. J AAPOS (2016) 0.77

Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol (2016) 0.76

Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2015) 0.76

Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema. JAMA Ophthalmol (2016) 0.76

Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.75

Author reply: To PMID 23337555. Ophthalmology (2014) 0.75

Author reply: To PMID 24084496. Ophthalmology (2014) 0.75

The Use of a Mobile Van for School Vision Screening: Results of 63 841 Evaluations. Am J Ophthalmol (2015) 0.75

Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents. JAMA Ophthalmol (2020) 0.75

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology (2020) 0.75

Comparison of cycloplegic refraction between Grand Seiko autorefractor and Retinomax autorefractor in the Vision in Preschoolers-Hyperopia in Preschoolers (VIP-HIP) Study. J AAPOS (2017) 0.75

Counterfeit Avastin in India: Punish the Criminals, Not the Patients. Am J Ophthalmol (2016) 0.75

Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmol Retina (2017) 0.75